xl228
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2007 (NCT00464113)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
IGF1R inhibitor
Also potent inhibitor of AURKA, AURKB, FGFR1-3, and ALK.
- Tyrosine-protein kinase ABLINHIBITOR
ABL1 inhibitor
Also potent inhibitor of AURKA, AURKB, FGFR1-3, and ALK.
- SRCINHIBITOR
SRC inhibitor
Also potent inhibitor of AURKA, AURKB, FGFR1-3, and ALK.
- Tyrosine-protein kinase Fyn (FYN) ↗
- Proto-oncogene tyrosine-protein kinase Src (SRC) ↗
- Tyrosine-protein kinase Lck (LCK) ↗
- Tyrosine-protein kinase Yes (YES1) ↗
- Tyrosine-protein kinase Blk (BLK) ↗
- Tyrosine-protein kinase HCK (HCK) ↗
- Tyrosine-protein kinase Lyn (LYN) ↗
- Tyrosine-protein kinase FRK (FRK) ↗
- Tyrosine-protein kinase Fgr (FGR) ↗
- Tyrosine-protein kinase Srms (SRMS) ↗
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1- Mol. weight
- 437.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545085 ↗
Also known as
- xl228
- xl228
- xl228
- xl-228
- xl-228
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00526838 | Phase 1 | Sep 1, 2007 | Exelixis |
| NCT00464113 | Phase 1 | May 1, 2007 | Exelixis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Exelixis | For profit | 2 | 2 | 1 | 2007 |
1 organizations
Page 1 / 1